SEC Form 4 · accession 0001209191-18-011670
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Haqq
Officer — EVP, R&D & Chief Scientific Of
Period of report
Feb 15, 2018
Accepted (ET)
Feb 20, 2018 · 8:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 15, 2018 | M | 553 | $0.00 | A | 351,232 | D | |
| Common StockF2 | holding | — | — | — | 17,312 | I | See footnote | |
| Common StockF3 | holding | — | — | — | 2,688 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4,F5,F6 | — | Feb 15, 2018 | M | 553 | D | — | — | Common Stock | 553 | 0 | D |
Explanation of responses
- F1Shares issued upon settlement of vested restricted stock units ("RSUs").
- F2The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
- F3The shares are held by The Havenside Trust, of which the Reporting Person is trustee.
- F4Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement.
- F5Fully vested.
- F6The earlier of (i) January 10, 2021 or (ii) the recipient's termination date.